Your browser is no longer supported. Please, upgrade your browser.
BTAI BioXcel Therapeutics, Inc. daily Stock Chart
BioXcel Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.36 Insider Own0.40% Shs Outstand18.97M Perf Week-22.81%
Market Cap841.57M Forward P/E- EPS next Y-3.13 Insider Trans0.00% Shs Float14.48M Perf Month-24.61%
Income-40.70M PEG- EPS next Q-0.75 Inst Own29.40% Short Float14.90% Perf Quarter-20.44%
Sales- P/S- EPS this Y-53.00% Inst Trans0.63% Short Ratio3.52 Perf Half Y1.49%
Book/sh3.83 P/B9.80 EPS next Y-2.60% ROA-81.30% Target Price- Perf Year332.76%
Cash/sh3.57 P/C10.51 EPS next 5Y- ROE-102.30% 52W Range3.76 - 71.50 Perf YTD156.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.52% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low897.87% ATR4.36
Employees27 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)32.62 Volatility7.64% 8.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-70.90% Profit Margin- Rel Volume4.36 Prev Close44.71
ShortableYes LT Debt/Eq0.00 EarningsAug 14 BMO Payout- Avg Volume612.25K Price37.52
Recom1.70 SMA20-27.11% SMA50-27.59% SMA20028.48% Volume2,670,779 Change-16.08%
Jul-08-20Reiterated H.C. Wainwright Buy $95 → $120
Jun-04-20Initiated Guggenheim Buy $101
Apr-01-20Initiated BofA/Merrill Buy $45
Feb-26-20Reiterated H.C. Wainwright Buy $30 → $95
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-12-19Initiated SunTrust Buy $24
Aug-14-20 12:34PM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Jul-28-20 08:20PM  
Jul-27-20 04:21PM  
Jul-22-20 05:45AM  
Jul-20-20 04:33PM  
Jul-09-20 07:00AM  
Jul-07-20 07:00AM  
Jul-05-20 09:21PM  
Jun-23-20 07:00AM  
Jun-17-20 09:43AM  
Jun-16-20 07:00AM  
Jun-15-20 04:05PM  
Jun-11-20 07:00AM  
Jun-04-20 09:42AM  
May-28-20 07:00AM  
May-15-20 05:45AM  
May-14-20 07:00AM  
May-12-20 10:31PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 07:00AM  
Apr-28-20 07:00AM  
Apr-24-20 07:21AM  
Mar-24-20 04:23PM  
Mar-19-20 07:15AM  
Mar-17-20 10:55AM  
Mar-09-20 07:00AM  
Mar-02-20 07:00AM  
Feb-28-20 08:20AM  
Feb-26-20 07:00AM  
Feb-20-20 07:30AM  
Feb-19-20 04:54PM  
Feb-18-20 07:00AM  
Feb-07-20 07:00AM  
Feb-06-20 07:47AM  
Feb-05-20 07:00AM  
Jan-28-20 06:13PM  
Jan-25-20 09:28AM  
Jan-10-20 06:45AM  
Jan-07-20 07:00AM  
Dec-30-19 07:00AM  
Dec-22-19 07:42PM  
Dec-11-19 07:00AM  
Dec-06-19 06:40AM  
Dec-03-19 07:00AM  
Nov-26-19 07:00AM  
Nov-21-19 06:30AM  
Nov-14-19 07:00AM  
Nov-07-19 07:00AM  
Oct-30-19 06:00AM  
Oct-27-19 09:51AM  
Oct-24-19 08:00AM  
Oct-10-19 08:00AM  
Sep-26-19 09:11AM  
Sep-25-19 04:27PM  
Sep-18-19 08:00AM  
Sep-04-19 08:00AM  
Aug-20-19 08:00AM  
Aug-06-19 07:30AM  
Jul-31-19 08:00AM  
Jul-30-19 04:01PM  
Jul-29-19 02:34PM  
Jul-26-19 12:21PM  
Jul-22-19 06:00AM  
Jul-01-19 08:00AM  
Jun-18-19 08:00AM  
Jun-10-19 08:00AM  
Jun-06-19 08:00AM  
Jun-03-19 08:00AM  
May-31-19 04:05PM  
May-28-19 11:02AM  
May-20-19 07:30AM  
May-13-19 08:00AM  
May-09-19 08:00AM  
May-07-19 08:00AM  
May-02-19 08:36AM  
Apr-29-19 05:17PM  
Apr-03-19 08:00AM  
Apr-01-19 08:03AM  
Mar-25-19 08:00AM  
Mar-13-19 04:01PM  
Mar-11-19 08:00AM  
Mar-07-19 08:00AM  
Mar-05-19 04:01PM  
Mar-04-19 08:00AM  
Mar-01-19 08:30AM  
Feb-06-19 08:00AM  
Feb-04-19 08:00AM  
Jan-09-19 08:50AM  
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yocca FrankChief Scientific OfficerFeb 14Option Exercise0.4180,00032,80088,397Feb 19 05:22 PM